Quantifying the efficacy of checkpoint inhibitors on CD8⁺ cytotoxic T cells for immunotherapeutic applications via single-cell interaction.

ABSTRACT: The inhibition of the PD1/PDL1 pathway has led to remarkable clinical success for cancer treatment in some patients. Many, however, exhibit little to no response to this treatment. To increase the efficacy of PD1 inhibition, additional checkpoint inhibitors are being explored as combination therapy options. TSR-042 and TSR-033 are novel antibodies for the inhibition of the PD1 and LAG3 pathways, respectively, and are intended for combination therapy. Here, we explore the effect on cellular interactions of TSR-042 and TSR-033 alone and in combination at the single-cell level. Utilizing our droplet microfluidic platform, we use time-lapse microscopy to observe the effects of these antibodies on calcium flux in CD8⁺ T cells upon antigen presentation, as well as their effect on the

SUBMITTER: Sullivan MR 

PROVIDER: S-EPMC7666200 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature